Literature DB >> 20103588

Evidence of receptor-mediated elimination of erythropoietin by analysis of erythropoietin receptor mRNA expression in bone marrow and erythropoietin clearance during anemia.

Demet Nalbant1, Mohammad Saleh, Frederic D Goldman, John A Widness, Peter Veng-Pedersen.   

Abstract

Erythropoietin (Epo) is the primary hormone that stimulates erythroid proliferation and differentiation through its cell surface receptor (EpoR) on erythroid progenitor cells. Previous studies have suggested that the bone marrow plays an important role in Epo's elimination. The changes in the EpoR mRNA levels and Epo's clearance in the bone marrow of 11 newborn lambs were studied to elucidate the role of EpoR in Epo's clearance under anemic conditions. Epo mRNA levels were measured by real-time polymerase chain reaction, and relative expression of EpoR was calculated by using the comparative CT method. The glyceraldehyde-3-phosphate dehydrogenase housekeeping gene was chosen as a control gene for the calculations. All lambs showed significant increase in bone marrow EpoR mRNA levels after phlebotomy-induced anemia. Epo's clearance determined from simultaneous pharmacokinetic studies with 125I-recombinant human Epo showed a significant increase after phlebotomy-induced anemia that was similar to the increase in EpoR. By day 28 after phlebotomy, EpoR mRNA levels and Epo clearance had returned toward baseline. These results indicate that the changes in Epo's clearance are not caused by body growth but result from significant changes in the pool of EpoR. A linear mixed-effect model was used to evaluate the quantitative relationship between EpoR and Epo's clearance. This analysis demonstrated a highly significant positive linear correlation between EpoR and Epo clearance. Together, these findings provide strong evidence that receptor-mediated Epo clearance is an important route for Epo's elimination.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20103588      PMCID: PMC2872962          DOI: 10.1124/jpet.109.163568

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  28 in total

1.  A new mathematical model for relative quantification in real-time RT-PCR.

Authors:  M W Pfaffl
Journal:  Nucleic Acids Res       Date:  2001-05-01       Impact factor: 16.971

2.  Curve fitting and modeling in pharmacokinetics and some practical experiences with NONLIN and a new program FUNFIT.

Authors:  P V Pedersen
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

3.  Receptor-based model accounts for phlebotomy-induced changes in erythropoietin pharmacokinetics.

Authors:  S H Chapel; P Veng-Pedersen; R L Schmidt; J A Widness
Journal:  Exp Hematol       Date:  2001-04       Impact factor: 3.084

4.  Quantitation of the mRNA levels of Epo and EpoR in various tissues in the ovine fetus.

Authors:  R Bruce David; Gaik Bee Lim; Karen M Moritz; Irene Koukoulas; E Marelyn Wintour
Journal:  Mol Cell Endocrinol       Date:  2002-02-25       Impact factor: 4.102

5.  The in vivo metabolism of recombinant human erythropoietin in the rat.

Authors:  J L Spivak; B B Hogans
Journal:  Blood       Date:  1989-01       Impact factor: 22.113

6.  Binding and receptor-mediated endocytosis of erythropoietin in Friend virus-infected erythroid cells.

Authors:  S T Sawyer; S B Krantz; E Goldwasser
Journal:  J Biol Chem       Date:  1987-04-25       Impact factor: 5.157

7.  Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling.

Authors:  Laura Calvillo; Roberto Latini; Jan Kajstura; Annarosa Leri; Piero Anversa; Pietro Ghezzi; Monica Salio; Anthony Cerami; Michael Brines
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-27       Impact factor: 11.205

8.  Hypoxia-ischemia affects erythropoietin and erythropoietin receptor expression pattern in the neonatal rat brain.

Authors:  Evangelia Spandou; Stamatia Papoutsopoulou; Vassiliki Soubasi; George Karkavelas; Constantina Simeonidou; George Kremenopoulos; Olympia Guiba-Tziampiri
Journal:  Brain Res       Date:  2004-09-24       Impact factor: 3.252

Review 9.  Molecular biology of erythropoietin.

Authors:  Wolfgang Jelkmann
Journal:  Intern Med       Date:  2004-08       Impact factor: 1.271

10.  Change in erythropoietin pharmacokinetics following hematopoietic transplantation.

Authors:  J A Widness; R L Schmidt; R J Hohl; F D Goldman; N H Al-Huniti; K J Freise; P Veng-Pedersen
Journal:  Clin Pharmacol Ther       Date:  2007-04-11       Impact factor: 6.875

View more
  13 in total

1.  Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575.

Authors:  Xiaoyu Yan; Philip J Lowe; Martin Fink; Alexander Berghout; Sigrid Balser; Wojciech Krzyzanski
Journal:  J Clin Pharmacol       Date:  2011-12-12       Impact factor: 3.126

2.  Characterization of erythropoietin and hepcidin in the regulation of persistent injury-associated anemia.

Authors:  Ines G Alamo; Kolenkode B Kannan; Michael A Smith; Philip A Efron; Alicia M Mohr
Journal:  J Trauma Acute Care Surg       Date:  2016-10       Impact factor: 3.313

Review 3.  Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents.

Authors:  Sameer Doshi; Wojciech Krzyzanski; Susan Yue; Steven Elliott; Andrew Chow; Juan José Pérez-Ruixo
Journal:  Clin Pharmacokinet       Date:  2013-12       Impact factor: 6.447

4.  Differential pharmacokinetic analysis of in vivo erythropoietin receptor interaction with erythropoietin and continuous erythropoietin receptor activator in sheep.

Authors:  Mohammed H El-Komy; Robert L Schmidt; John A Widness; Peter Veng-Pedersen
Journal:  Biopharm Drug Dispos       Date:  2011-06-15       Impact factor: 1.627

5.  Daily propranolol administration reduces persistent injury-associated anemia after severe trauma and chronic stress.

Authors:  Ines G Alamo; Kolenkode B Kannan; Letitia E Bible; Tyler J Loftus; Harry Ramos; Philip A Efron; Alicia M Mohr
Journal:  J Trauma Acute Care Surg       Date:  2017-04       Impact factor: 3.313

6.  Pharmacodynamic analysis of stress erythropoiesis: change in erythropoietin receptor pool size following double phlebotomies in sheep.

Authors:  Mohammad I Saleh; John A Widness; Peter Veng-Pedersen
Journal:  Biopharm Drug Dispos       Date:  2011-01-10       Impact factor: 1.627

7.  Receptor-based dosing optimization of erythropoietin in juvenile sheep after phlebotomy.

Authors:  Matthew Rosebraugh; John A Widness; Peter Veng-Pedersen
Journal:  Drug Metab Dispos       Date:  2011-04-01       Impact factor: 3.922

8.  Severe trauma and chronic stress activates extramedullary erythropoiesis.

Authors:  Ines G Alamo; Kolenkode B Kannan; Tyler J Loftus; Harry Ramos; Philip A Efron; Alicia M Mohr
Journal:  J Trauma Acute Care Surg       Date:  2017-07       Impact factor: 3.313

Review 9.  Erythropoietin doping in cycling: lack of evidence for efficacy and a negative risk-benefit.

Authors:  Jules A A C Heuberger; Joost M Cohen Tervaert; Femke M L Schepers; Adriaan D B Vliegenthart; Joris I Rotmans; Johannes M A Daniels; Jacobus Burggraaf; Adam F Cohen
Journal:  Br J Clin Pharmacol       Date:  2013-06       Impact factor: 4.335

10.  Erythropoietin for neuroprotection in neonatal encephalopathy: safety and pharmacokinetics.

Authors:  Yvonne W Wu; Larry A Bauer; Roberta A Ballard; Donna M Ferriero; David V Glidden; Dennis E Mayock; Taeun Chang; David J Durand; Dongli Song; Sonia L Bonifacio; Fernando F Gonzalez; Hannah C Glass; Sandra E Juul
Journal:  Pediatrics       Date:  2012-09-24       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.